These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 35461077

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in blaKPC-2-Harboring Klebsiella pneumoniae Sequence Type 307 Isolates.
    Giddins MJ, Macesic N, Annavajhala MK, Stump S, Khan S, McConville TH, Mehta M, Gomez-Simmonds A, Uhlemann AC.
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Acquisition of a Stable and Transferable blaNDM-5-Positive Plasmid With Low Fitness Cost Leading to Ceftazidime/Avibactam Resistance in KPC-2-Producing Klebsiella pneumoniae During Treatment.
    Huang J, Zhang S, Zhao Z, Chen M, Cao Y, Li B.
    Front Cell Infect Microbiol; 2021 Mar; 11():658070. PubMed ID: 34354959
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient.
    Gaibani P, Gatti M, Rinaldi M, Crovara Pesce C, Lazzarotto T, Giannella M, Lombardo D, Amadesi S, Viale P, Pea F, Ambretti S.
    Int J Infect Dis; 2021 Dec; 113():213-217. PubMed ID: 34656787
    [Abstract] [Full Text] [Related]

  • 9. Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae.
    Guo Y, Liu N, Lin Z, Ba X, Zhuo C, Li F, Wang J, Li Y, Yao L, Liu B, Xiao S, Jiang Y, Zhuo C.
    Emerg Microbes Infect; 2021 Dec; 10(1):2042-2051. PubMed ID: 34551677
    [Abstract] [Full Text] [Related]

  • 10. Emergence of transferable ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae due to a novel CMY AmpC β-lactamase in China.
    Xu M, Zhao J, Xu L, Yang Q, Xu H, Kong H, Zhou J, Fu Y.
    Clin Microbiol Infect; 2022 Jan; 28(1):136.e1-136.e6. PubMed ID: 34044150
    [Abstract] [Full Text] [Related]

  • 11. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.
    Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi Y, Kreiswirth BN, Nguyen MH, Clancy CJ.
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
    [Abstract] [Full Text] [Related]

  • 12. Colonization by ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae following therapy in critically ill patients.
    Gaibani P, Bovo F, Bussini L, Bartoletti M, Lazzarotto T, Viale P, Pea F, Ambretti S.
    Clin Microbiol Infect; 2023 May; 29(5):654.e1-654.e4. PubMed ID: 36716999
    [Abstract] [Full Text] [Related]

  • 13. Ceftazidime-Avibactam resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae: A phenotypic and genotypic analysis.
    Krithika VM, Ganesan V, Rajendran T.
    Indian J Med Microbiol; 2024 May; 49():100603. PubMed ID: 38705276
    [Abstract] [Full Text] [Related]

  • 14. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.
    Di Pilato V, Principe L, Andriani L, Aiezza N, Coppi M, Ricci S, Giani T, Luzzaro F, Rossolini GM.
    Clin Microbiol Infect; 2023 Apr; 29(4):537.e1-537.e8. PubMed ID: 36414199
    [Abstract] [Full Text] [Related]

  • 15. Emergence of ceftazidime-avibactam resistance in blaKPC-33-harbouring ST11 Klebsiella pneumoniae in a paediatric patient.
    Zhou J, Yan G, Tang C, Liu J, Fu P, Ding L, Yang W, Guo Y, Wang C, Lu G, Hu F.
    Int J Antimicrob Agents; 2024 Jun; 63(6):107163. PubMed ID: 38570018
    [Abstract] [Full Text] [Related]

  • 16. KPC-2 allelic variants in Klebsiella pneumoniae isolates resistant to ceftazidime-avibactam from Argentina: blaKPC-80, blaKPC-81, blaKPC-96 and blaKPC-97.
    Sanz MB, Pasteran F, de Mendieta JM, Brunetti F, Albornoz E, Rapoport M, Lucero C, Errecalde L, Nuñez MR, Monge R, Pennini M, Power P, Corso A, Gomez SA.
    Microbiol Spectr; 2024 Mar 05; 12(3):e0411123. PubMed ID: 38319084
    [Abstract] [Full Text] [Related]

  • 17. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.
    Gaibani P, Campoli C, Lewis RE, Volpe SL, Scaltriti E, Giannella M, Pongolini S, Berlingeri A, Cristini F, Bartoletti M, Tedeschi S, Ambretti S.
    J Antimicrob Chemother; 2018 Jun 01; 73(6):1525-1529. PubMed ID: 29566151
    [Abstract] [Full Text] [Related]

  • 18. Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering.
    Barnes MD, Winkler ML, Taracila MA, Page MG, Desarbre E, Kreiswirth BN, Shields RK, Nguyen MH, Clancy C, Spellberg B, Papp-Wallace KM, Bonomo RA.
    mBio; 2017 Oct 31; 8(5):. PubMed ID: 29089425
    [Abstract] [Full Text] [Related]

  • 19. Ceftazidime-avibactam resistance determination in carbapenem-resistant Klebsiella pneumoniae infections before its use in practice.
    Eren-Kutsoylu OÖ, Ceylan-Çimendağ H, Sari-Kaygisiz AN, Tanriverdi ES, Özbek ÖA, Öktem IMA, Otlu B, Avkan-Oğuz V.
    J Infect Dev Ctries; 2024 Jul 29; 18(7):1020-1025. PubMed ID: 39078779
    [Abstract] [Full Text] [Related]

  • 20. Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort.
    Castón JJ, Gallo M, García M, Cano A, Escribano A, Machuca I, Gracia-Aufinger I, Guzman-Puche J, Pérez-Nadales E, Recio M, Muñoz M, Martínez-Martínez L, Torre-Cisneros J, Spanish Network for Research in Infectious Diseases (REIPI).
    Int J Antimicrob Agents; 2020 Sep 29; 56(3):106075. PubMed ID: 32629116
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.